Floatz logo

Eloxatin

KRAS G12C

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the KRAS G12C cohort.

Asset / SponsorPhaseRating
Opnurasib
Maastricht University Medical Center
Phase 2CCC
Sotorasib
ETOP IBCSG Partners Foundation
Phase 2CCC
LENVATINIB
ETOP IBCSG Partners Foundation
Phase 2CCC
Adagrasib
Ryan Gentzler, MD
Phase 2CCC
Fulzerasib
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2CCC

View all 23 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →